Vaxxinity is a U.S.-based global biotechnology company pioneering a new class of medicines to democratize health. Headquartered in Dallas, TX, with operations in the United States, Latin America, Europe and Asia, the company’s proprietary technology platform has enabled the innovation of synthetic peptide vaccines designed to prevent or treat infectious diseases, including COVID-19, and chronic diseases, including Alzheimer's, Parkinson’s, migraine, and hypercholesterolemia.. Vaxxinity has optimized its pipeline to achieve a potentially historic, global impact on human health. The key to the platform is the proprietary library of UBITh peptides, which are immunosilent, avoiding inflammation, and when linked to custom-designed target antigens, can elicit highly specific antibodies.
| Website | http://www.vaxxinity.com |
| Employees | 78 (14 on RocketReach) |
| Technologies |
JavaScript
,
HTML
,
PHP
+41 more
(view full list)
|
| Industry | Biotechnology Research |
| Keywords | Biotechnology, Vaccine Development, Drug Discovery, Medicine, Pharmaceutical, Research And Development, Immunotherapy, Pharmaceutical Research, Therapeutic Vaccines, Novel Therapeutics, Immunology Research, Biologics, Clinical Trials, Infectious Disease, Prevention, Protein Therapeutics, Neurological Disorders, Health Solutions, Global Health |
| Competitors | Johnson & Johnson, Merck & Co., Inc., Pfizer, Sanofi, GSK, AstraZeneca, Bristol Myers Squibb, Biogen, Moderna Therapeutics, Novavax +36 more (view full list) |
Looking for a particular Vaxxinity employee's phone or email?
Maggie Lewis is the Vice President, Regulatory Affairs and Medical Writing of Vaxxinity.
14 people are employed at Vaxxinity.